Difference between revisions of "Acute myeloid leukemia, NPM1-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "http://www.ncbi.nlm.nih.gov/pmc" to "https://www.ncbi.nlm.nih.gov/pmc")
 
(10 intermediate revisions by 2 users not shown)
Line 12: Line 12:
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 
=Guidelines=
 
=Guidelines=
−
==[https://www.nccn.org/ NCCN]==
+
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
−
*''NCCN does not have guidelines at this granular level; please see [https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf NCCN Guidelines - Acute Myeloid Leukemia].''
+
==NCCN==
 +
*''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411 NCCN Guidelines - Acute Myeloid Leukemia].''
 
=Upfront induction therapy=
 
=Upfront induction therapy=
−
==Cytarabine & Etoposide {{#subobject:e8gacb|Regimen=1}}==
 
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen {{#subobject:15hvdd|Variant=1}}===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Dates of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://www.clinicaltrials.gov/study/NCT01237808 Awaiting publication (AMLSG 15-10)]
 
−
|2011-NR
 
−
| style="background-color:#1a9851" |Phase 3 (C)
 
−
|[[Stub#ATRA.2C_Cytarabine.2C_Etoposide|ATRA, Cytarabine, Etoposide]]
 
−
| style="background-color:#d3d3d3" |Not available
 
−
|-
 
−
|}
 
−
<div class="toccolours" style="background-color:#b3e2cd">
 
−
====Chemotherapy====
 
−
*[[Cytarabine (Ara-C)]]
 
−
*[[Etoposide (Vepesid)]]
 
−
</div></div>
 
−
===References===
 
−
#'''AMLSG 15-10:''' [https://clinicaltrials.gov/study/NCT01237808 NCT01237808]
 
 
==ICE & ATRA {{#subobject:e82156|Regimen=1}}==
 
==ICE & ATRA {{#subobject:e82156|Regimen=1}}==
 
ICE & ATRA: '''<u>I</u>'''darubicin, '''<u>C</u>'''ytarabine, '''<u>E</u>'''toposide, '''<u>A</u>'''ll-'''<u>T</u>'''rans '''<u>R</u>'''etinoic '''<u>A</u>'''cid
 
ICE & ATRA: '''<u>I</u>'''darubicin, '''<u>C</u>'''ytarabine, '''<u>E</u>'''toposide, '''<u>A</u>'''ll-'''<u>T</u>'''rans '''<u>R</u>'''etinoic '''<u>A</u>'''cid
Line 54: Line 31:
 
| style="background-color:#1a9851" |Phase 3 (C)
 
| style="background-color:#1a9851" |Phase 3 (C)
 
|[[Stub#ICE.2C_ATRA.2C_GO|ICE, ATRA, GO]]
 
|[[Stub#ICE.2C_ATRA.2C_GO|ICE, ATRA, GO]]
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of EFS
+
| style="background-color:#fee08b" |Might have inferior EFS6<sup>1</sup> (co-primary endpoint)
 
|-
 
|-
 
|}
 
|}
 +
''<sup>1</sup>Reported efficacy is based on the 2023 update.''
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
Line 72: Line 50:
 
<div class="toccolours" style="background-color:#cbd5e7">
 
<div class="toccolours" style="background-color:#cbd5e7">
 
====Subsequent treatment====
 
====Subsequent treatment====
−
*[[#HiDAC_.26_ATRA_888|HiDAC & ATRA]] consolidation
+
*[[#HiDAC_.26_ATRA|HiDAC & ATRA]] consolidation
 
</div></div><br>
 
</div></div><br>
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
Line 87: Line 65:
 
| style="background-color:#1a9851" |Phase 3 (C)
 
| style="background-color:#1a9851" |Phase 3 (C)
 
|[[Stub#ICE.2C_ATRA.2C_GO|ICE, ATRA, GO]]
 
|[[Stub#ICE.2C_ATRA.2C_GO|ICE, ATRA, GO]]
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of EFS
+
| style="background-color:#fee08b" |Might have inferior EFS6<sup>1</sup> (co-primary endpoint)
 
|-
 
|-
 
|}
 
|}
 +
''<sup>1</sup>Reported efficacy is based on the 2023 update.''
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
 
====Chemotherapy====
 
====Chemotherapy====
Line 101: Line 80:
 
<div class="toccolours" style="background-color:#cbd5e7">
 
<div class="toccolours" style="background-color:#cbd5e7">
 
====Subsequent treatment====
 
====Subsequent treatment====
−
*[[#HiDAC_.26_ATRA_888|HiDAC & ATRA]] consolidation
+
*[[#HiDAC_.26_ATRA|HiDAC & ATRA]] consolidation
 
</div></div>
 
</div></div>
 
===References===
 
===References===
 
# '''AMLSG 09-09:''' Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Horst HA, Koller E, Wulf G, Schleicher J, Bentz M, Greil R, Hertenstein B, Krauter J, Martens U, Nachbaur D, Abu Samra M, Girschikofsky M, Basara N, Benner A, Thol F, Heuser M, Ganser A, Döhner K, Döhner H. Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. J Clin Oncol. 2020 Feb 20;38(6):623-632. Epub 2019 Dec 18. [https://doi.org/10.1200/JCO.19.01406 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7030890/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/31851556/ PubMed] [https://clinicaltrials.gov/study/NCT00893399 NCT00893399]
 
# '''AMLSG 09-09:''' Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Horst HA, Koller E, Wulf G, Schleicher J, Bentz M, Greil R, Hertenstein B, Krauter J, Martens U, Nachbaur D, Abu Samra M, Girschikofsky M, Basara N, Benner A, Thol F, Heuser M, Ganser A, Döhner K, Döhner H. Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. J Clin Oncol. 2020 Feb 20;38(6):623-632. Epub 2019 Dec 18. [https://doi.org/10.1200/JCO.19.01406 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7030890/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/31851556/ PubMed] [https://clinicaltrials.gov/study/NCT00893399 NCT00893399]
 +
##'''Update:''' Döhner H, Weber D, Krzykalla J, Fiedler W, Kühn MWM, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Fransecky L, Koller E, Wulf G, Schleicher J, Ringhoffer M, Greil R, Hertenstein B, Krauter J, Martens UM, Nachbaur D, Samra MA, Machherndl-Spandl S, Basara N, Leis C, Schrade A, Kapp-Schwoerer S, Cocciardi S, Bullinger L, Thol F, Heuser M, Paschka P, Gaidzik VI, Saadati M, Benner A, Schlenk RF, Döhner K, Ganser A; German–Austrian AML Study Group. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2023 Jul;10(7):e495-e509. Epub 2023 May 12. [https://doi.org/10.1016/s2352-3026(23)00089-3 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37187198/ PubMed]
 +
 +
=First-line induction therapy, older or "unfit" patients=
 +
''Note: these regimens are generally considered to be part of a non-curative line of treatment.''
 +
==Cytarabine & Etoposide (CYVE) {{#subobject:e8gacb|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:15hvdd|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 +
!style="width: 20%"|Study
 +
!style="width: 20%"|Dates of enrollment
 +
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 20%"|Comparator
 +
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10491626/ Schlenk et al. 2023 (AMLSG 15-10)]
 +
|2011-05-11 to 2016-09-14
 +
| style="background-color:#1a9851" |Phase 3 (C)
 +
|[[Stub#ATRA.2C_Cytarabine.2C_Etoposide|ATRA, Cytarabine, Etoposide]]
 +
| style="background-color:#91cf60" |Seems to have superior OS (primary endpoint)
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Cytarabine (Ara-C)]] 20 mg SC twice per day on days 1 to 7
 +
*[[Etoposide (Vepesid)]] as follows:
 +
**Cycle 1: 50 mg/m<sup>2</sup> PO or IV once per day on days 1 to 3
 +
**Cycle 2 to 6: 100 mg/m<sup>2</sup> PO or IV once per day on days 1 to 3
 +
'''28-day cycle for 6 cycles'''
 +
</div></div>
 +
===References===
 +
#'''AMLSG 15-10:''' Schlenk RF, Weber D, Krzykalla J, Kindler T, Wulf G, Hertenstein B, Salih HR, Südhoff T, Krauter J, Martens U, Wessendorf S, Runde V, Tischler HJ, Bentz M, Koller E, Heuser M, Thol F, Benner A, Ganser A, Döhner K, Döhner H. Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia. Sci Rep. 2023 Sep 8;13(1):14809. [https://doi.org/10.1038/s41598-023-41964-y link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10491626/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/37684299/ PubMed] [https://clinicaltrials.gov/study/NCT01237808 NCT01237808]
 +
 +
=Consolidation after upfront therapy=
 +
==HiDAC & ATRA {{#subobject:e0396d|Regimen=1}}==
 +
HiDAC & ATRA: '''<u>Hi</u>'''gh '''<u>D</u>'''ose '''<u>A</u>'''ra-'''<u>C</u>''' (Cytarabine) &  '''<u>A</u>'''ll-'''<u>T</u>'''rans '''<u>R</u>'''etinoic '''<u>A</u>'''cid
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:d8edc4|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 +
!style="width: 33%"|Study
 +
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7030890/ Schlenk et al. 2019 (AMLSG 09-09)]
 +
|2010-2017
 +
| style="background-color:#91cf61" |Non-randomized part of phase 3 RCT
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#cbd5e8">
 +
====Preceding treatment====
 +
*[[##ICE_.26_ATRA|ICE & ATRA]] induction
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Chemotherapy====
 +
*[[Cytarabine (Ara-C)]] by the following age-based criteria:
 +
**18 to 60 years old: 3000 mg/m<sup>2</sup> IV every 12 hours on days 1 to 3 (6 doses total)
 +
**Older than 60 years old: 1000 mg/m<sup>2</sup> IV every 12 hours on days 1 to 3 (6 doses total)
 +
====Targeted therapy====
 +
*[[All-trans retinoic acid (ATRA)]] 15 mg/m<sup>2</sup> PO once per day on days 4 to 21
 +
====Supportive therapy====
 +
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 8
 +
'''3 cycles'''
 +
===References===
 +
# '''AMLSG 09-09:''' Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Horst HA, Koller E, Wulf G, Schleicher J, Bentz M, Greil R, Hertenstein B, Krauter J, Martens U, Nachbaur D, Abu Samra M, Girschikofsky M, Basara N, Benner A, Thol F, Heuser M, Ganser A, Döhner K, Döhner H. Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. J Clin Oncol. 2020 Feb 20;38(6):623-632. Epub 2019 Dec 18. [https://doi.org/10.1200/JCO.19.01406 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7030890/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/31851556/ PubMed] [https://clinicaltrials.gov/study/NCT00893399 NCT00893399]
 +
##'''Update:''' Döhner H, Weber D, Krzykalla J, Fiedler W, Kühn MWM, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Fransecky L, Koller E, Wulf G, Schleicher J, Ringhoffer M, Greil R, Hertenstein B, Krauter J, Martens UM, Nachbaur D, Samra MA, Machherndl-Spandl S, Basara N, Leis C, Schrade A, Kapp-Schwoerer S, Cocciardi S, Bullinger L, Thol F, Heuser M, Paschka P, Gaidzik VI, Saadati M, Benner A, Schlenk RF, Döhner K, Ganser A; German–Austrian AML Study Group. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2023 Jul;10(7):e495-e509. Epub 2023 May 12. [https://doi.org/10.1016/s2352-3026(23)00089-3 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37187198/ PubMed]
 
[[Category:Acute myeloid leukemia regimens]]
 
[[Category:Acute myeloid leukemia regimens]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Acute leukemias]]
 
[[Category:Acute leukemias]]

Latest revision as of 12:16, 23 June 2024

Back to Top

Section editor
AK.JPG
 Ashwin Kishtagari, MD
Vanderbilt University
Nashville, TN, USA
LinkedIn

Note: these are regimens tested in biomarker-specific populations for patients with NPM1-mutated AML, please see the main AML page for other regimens.

3 regimens on this page
4 variants on this page


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

NCCN

Upfront induction therapy

ICE & ATRA

ICE & ATRA: Idarubicin, Cytarabine, Etoposide, All-Trans Retinoic Acid

Regimen variant #1, 60 or younger

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Schlenk et al. 2019 (AMLSG 09-09) 2010-2017 Phase 3 (C) ICE, ATRA, GO Might have inferior EFS61 (co-primary endpoint)

1Reported efficacy is based on the 2023 update.

Chemotherapy

  • Idarubicin (Idamycin) as follows:
    • Cycle 1: 12 mg/m2 IV once per day on days 1, 3, 5
    • Cycle 2: 12 mg/m2 IV once per day on days 1 & 3
  • Cytarabine (Ara-C) 100 mg/m2/day IV continuous infusion over 7 days, started on day 1 (total dose per cycle: 700 mg/m2)
  • Etoposide (Vepesid) as follows:
    • Cycle 1: 100 mg/m2 IV once per day on days 1 to 3
    • Cycle 2: 100 mg/m2 IV once per day on days 1 & 3

Targeted therapy

2 cycles

Subsequent treatment


Regimen variant #2, older than 60

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Schlenk et al. 2019 (AMLSG 09-09) 2010-2017 Phase 3 (C) ICE, ATRA, GO Might have inferior EFS61 (co-primary endpoint)

1Reported efficacy is based on the 2023 update.

Chemotherapy

Targeted therapy

2 cycles

Subsequent treatment

References

  1. AMLSG 09-09: Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Horst HA, Koller E, Wulf G, Schleicher J, Bentz M, Greil R, Hertenstein B, Krauter J, Martens U, Nachbaur D, Abu Samra M, Girschikofsky M, Basara N, Benner A, Thol F, Heuser M, Ganser A, Döhner K, Döhner H. Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. J Clin Oncol. 2020 Feb 20;38(6):623-632. Epub 2019 Dec 18. link to original article link to PMC article contains dosing details in manuscript PubMed NCT00893399
    1. Update: Döhner H, Weber D, Krzykalla J, Fiedler W, Kühn MWM, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Fransecky L, Koller E, Wulf G, Schleicher J, Ringhoffer M, Greil R, Hertenstein B, Krauter J, Martens UM, Nachbaur D, Samra MA, Machherndl-Spandl S, Basara N, Leis C, Schrade A, Kapp-Schwoerer S, Cocciardi S, Bullinger L, Thol F, Heuser M, Paschka P, Gaidzik VI, Saadati M, Benner A, Schlenk RF, Döhner K, Ganser A; German–Austrian AML Study Group. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2023 Jul;10(7):e495-e509. Epub 2023 May 12. link to original article PubMed

First-line induction therapy, older or "unfit" patients

Note: these regimens are generally considered to be part of a non-curative line of treatment.

Cytarabine & Etoposide (CYVE)

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Schlenk et al. 2023 (AMLSG 15-10) 2011-05-11 to 2016-09-14 Phase 3 (C) ATRA, Cytarabine, Etoposide Seems to have superior OS (primary endpoint)

Chemotherapy

  • Cytarabine (Ara-C) 20 mg SC twice per day on days 1 to 7
  • Etoposide (Vepesid) as follows:
    • Cycle 1: 50 mg/m2 PO or IV once per day on days 1 to 3
    • Cycle 2 to 6: 100 mg/m2 PO or IV once per day on days 1 to 3

28-day cycle for 6 cycles

References

  1. AMLSG 15-10: Schlenk RF, Weber D, Krzykalla J, Kindler T, Wulf G, Hertenstein B, Salih HR, Südhoff T, Krauter J, Martens U, Wessendorf S, Runde V, Tischler HJ, Bentz M, Koller E, Heuser M, Thol F, Benner A, Ganser A, Döhner K, Döhner H. Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia. Sci Rep. 2023 Sep 8;13(1):14809. link to original article link to PMC article contains dosing details in manuscript PubMed NCT01237808

Consolidation after upfront therapy

HiDAC & ATRA

HiDAC & ATRA: High Dose Ara-C (Cytarabine) & All-Trans Retinoic Acid

Regimen

Study Dates of enrollment Evidence
Schlenk et al. 2019 (AMLSG 09-09) 2010-2017 Non-randomized part of phase 3 RCT

Preceding treatment

Chemotherapy

  • Cytarabine (Ara-C) by the following age-based criteria:
    • 18 to 60 years old: 3000 mg/m2 IV every 12 hours on days 1 to 3 (6 doses total)
    • Older than 60 years old: 1000 mg/m2 IV every 12 hours on days 1 to 3 (6 doses total)

Targeted therapy

Supportive therapy

3 cycles

References

  1. AMLSG 09-09: Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Horst HA, Koller E, Wulf G, Schleicher J, Bentz M, Greil R, Hertenstein B, Krauter J, Martens U, Nachbaur D, Abu Samra M, Girschikofsky M, Basara N, Benner A, Thol F, Heuser M, Ganser A, Döhner K, Döhner H. Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. J Clin Oncol. 2020 Feb 20;38(6):623-632. Epub 2019 Dec 18. link to original article link to PMC article contains dosing details in manuscript PubMed NCT00893399
    1. Update: Döhner H, Weber D, Krzykalla J, Fiedler W, Kühn MWM, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Fransecky L, Koller E, Wulf G, Schleicher J, Ringhoffer M, Greil R, Hertenstein B, Krauter J, Martens UM, Nachbaur D, Samra MA, Machherndl-Spandl S, Basara N, Leis C, Schrade A, Kapp-Schwoerer S, Cocciardi S, Bullinger L, Thol F, Heuser M, Paschka P, Gaidzik VI, Saadati M, Benner A, Schlenk RF, Döhner K, Ganser A; German–Austrian AML Study Group. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2023 Jul;10(7):e495-e509. Epub 2023 May 12. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Acute_myeloid_leukemia,_NPM1-mutated&oldid=86392"